Literature DB >> 17309812

How to improve accrual to clinical trials of symptom control 1: recruitment strategies.

Andrew J Vickers1.   

Abstract

Inadequate patient accrual remains the primary problem for clinical trials of integrative therapies for symptom control. Many difficulties can be predicted and avoided if a careful, evidence-based approach to trial design is taken: trialists should attempt to get as many data as possible on the study population by querying institutional databases, examining case notes, following inpatient rounds, and conducting "dry runs" by asking doctors for referrals. Trials require aggressive recruitment strategies, including advertising, writing to patients at home, scanning clinic lists, and identifying critical points during clinical care at which patients can be approached. The information given to patients during any initial contact should be as simple and general as possible: presenting too much information too soon can be overwhelming and off-putting.

Entities:  

Mesh:

Year:  2007        PMID: 17309812      PMCID: PMC2596475          DOI: 10.2310/7200.2006.034

Source DB:  PubMed          Journal:  J Soc Integr Oncol        ISSN: 1715-894X


  7 in total

1.  Why randomized controlled trials fail but needn't: 1. Failure to gain "coal-face" commitment and to use the uncertainty principle.

Authors:  D L Sackett
Journal:  CMAJ       Date:  2000-05-02       Impact factor: 8.262

2.  Accruing large numbers of patients in primary care trials by retrospective recruitment methods.

Authors:  R McCarney; P Fisher; R van Haselen
Journal:  Complement Ther Med       Date:  2002-06       Impact factor: 2.446

3.  The impact of the physician on the accrual to randomized clinical trials in patients with primary operable breast cancer.

Authors:  R Kaas; A A M Hart; E J Th Rutgers
Journal:  Breast       Date:  2005-08       Impact factor: 4.380

4.  Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001.

Authors:  Gretchen G Kimmick; Bercedis L Peterson; Alice B Kornblith; Jeanne Mandelblatt; Jeffrey L Johnson; Judith Wheeler; Robin Heinze; Harvey J Cohen; Hyman B Muss
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

5.  Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment.

Authors:  P N Lara; R Higdon; N Lim; K Kwan; M Tanaka; D H Lau; T Wun; J Welborn; F J Meyers; S Christensen; R O'Donnell; C Richman; S A Scudder; J Tuscano; D R Gandara; K S Lam
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

6.  Randomized, controlled trial of an easy-to-read informed consent statement for clinical trial participation: a study of the Eastern Cooperative Oncology Group.

Authors:  Cathy A Coyne; Ronghui Xu; Peter Raich; Kathy Plomer; Mark Dignan; Lari B Wenzel; Diane Fairclough; Thomas Habermann; Linda Schnell; Susan Quella; David Cella
Journal:  J Clin Oncol       Date:  2003-03-01       Impact factor: 44.544

7.  Improving accrual into cancer clinical trials.

Authors:  J F Foley; C G Moertel
Journal:  J Cancer Educ       Date:  1991       Impact factor: 2.037

  7 in total
  3 in total

Review 1.  Which botanicals or other unconventional anticancer agents should we take to clinical trial?

Authors:  Andrew J Vickers
Journal:  J Soc Integr Oncol       Date:  2007

2.  Recruitment strategies for an acupuncture randomized clinical trial of reproductive age women.

Authors:  Lisa M Pastore; Parchayi Dalal
Journal:  Complement Ther Med       Date:  2009-05-12       Impact factor: 2.446

3.  How to improve accrual to clinical trials of symptom control 2: design issues.

Authors:  Andrew J Vickers
Journal:  J Soc Integr Oncol       Date:  2007
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.